Growth Metrics

Verastem (VSTM) Current Deferred Revenue (2011 - 2023)

Verastem's quarterly Current Deferred Revenue came in at $327000.0 in Q4 2023, up 68.56% quarter-over-quarter from $194000.0 in Q1 2018.

Verastem has reported Current Deferred Revenue for 9 years, with the latest figure at $327000.0 in Q4 2023.

  • For the quarter ending Q4 2023, Current Deferred Revenue changed N/A year-over-year to $327000.0; the trailing twelve-month figure through Dec 2023 stood at $327000.0 (changed N/A YoY), and the FY2023 full-year result was $327000.0, changed N/A from the prior year.
  • Current Deferred Revenue for Q4 2023 stood at $327000.0, up from $194000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $327000.0 in Q4 2023, with the low at $327000.0 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Verastem 425.60 Mn 243.93 Mn 15.90 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 327,000.00
Mar 31, 2018 194,000.00
Dec 31, 2017 190,000.00
Sep 30, 2017 186,000.00
Jun 30, 2017 81,000.00
Mar 31, 2017 179,000.00
Dec 31, 2016 527,000.00
Sep 30, 2016 171,000.00
Jun 30, 2016 167,000.00
Mar 31, 2016 164,000.00
Dec 31, 2015 160,000.00
Sep 30, 2015 156,000.00
Jun 30, 2015 152,000.00
Mar 31, 2015 148,000.00
Dec 31, 2014 144,000.00
Sep 30, 2014 137,000.00
Jun 30, 2014 72,000.00
Mar 31, 2014 28,000.00
Dec 31, 2013 38,000.00
Sep 30, 2013 43,000.00
Jun 30, 2013 41,000.00
Mar 31, 2013 39,000.00
Dec 31, 2012 36,000.00
Sep 30, 2012 34,000.00
Jun 30, 2012 32,000.00
Dec 31, 2011 27,000.00